{"id":"rhfsh-rhlh","safety":{"commonSideEffects":[{"rate":null,"effect":"Ovarian hyperstimulation syndrome (OHSS)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain/bloating"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Follicle-stimulating hormone (FSH) promotes the growth and maturation of ovarian follicles, while luteinizing hormone (LH) triggers the final maturation and ovulation of the egg. The combination of recombinant FSH and LH mimics the natural hormonal cascade required for successful ovulation in assisted reproductive technology cycles.","oneSentence":"rhFSH and rhLH are recombinant human gonadotropins that stimulate follicle development and ovulation in women undergoing fertility treatment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:04:53.703Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Infertility in women undergoing assisted reproductive technology (ART)"},{"name":"Anovulation and ovulatory disorders"}]},"trialDetails":[{"nctId":"NCT04719000","phase":"PHASE4","title":"PErsonalized Addition of Recombinant LH in Ovarian Stimulation","status":"RECRUITING","sponsor":"Fundación Santiago Dexeus Font","startDate":"2021-02-04","conditions":"Infertility","enrollment":120},{"nctId":"NCT02047227","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2014-01-31","conditions":"Infertility","enrollment":939},{"nctId":"NCT01029470","phase":"PHASE2","title":"To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2009-12","conditions":"Infertility","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"rhFSH+rhLH","genericName":"rhFSH+rhLH","companyName":"Fundación Santiago Dexeus Font","companyId":"fundaci-n-santiago-dexeus-font","modality":"Small molecule","firstApprovalDate":"","aiSummary":"rhFSH and rhLH are recombinant human gonadotropins that stimulate follicle development and ovulation in women undergoing fertility treatment. Used for Infertility in women undergoing assisted reproductive technology (ART), Anovulation and ovulatory disorders.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}